The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUnicorn Asset Management Regulatory News (UAV)

Share Price Information for Unicorn Asset Management (UAV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 92.50
Bid: 89.00
Ask: 96.00
Change: 3.50 (3.78%)
Spread: 7.00 (7.865%)
Open: 92.50
High: 96.00
Low: 96.00
Prev. Close: 92.50
UAV Live PriceLast checked at -
Unicorn AIM VCT is an Investment Trust

To provide shareholders with an attractive return from a diversified portfolio, predominantly invested in the shares of AIM quoted companies by maintaining dividend distributions to shareholders.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

16 Jan 2018 11:30

RNS Number : 0217C
Unicorn AIM VCT PLC
16 January 2018
 

Unicorn AIM VCT plc ("the Company")

LEI: 21380057QDV7D34E9870

Interim Management Statement 

For the period from 1 October 2017 to 31 December 2017

 

Introduction

 

This voluntary Interim Management Statement (IMS) covers the three month period ended 31 December 2017, together with relevant information up to the date of publication. 

 

Investment Objective

 

The Company's objective is to provide Shareholders with an attractive return from a diversified portfolio of investments, predominantly in the shares of AIM quoted companies, by maintaining a steady flow of dividend distributions to Shareholders from the capital gains as well as income generated by the portfolio.

 

It is also the objective that the Company should continue to qualify as a Venture Capital Trust, so that Shareholders benefit from the taxation advantages that this brings. To achieve this at least 70% of the Company's total assets are to be invested in qualifying investments of which 30% by VCT value (70% for funds raised after 6 April 2011) must be in ordinary shares carrying no preferential rights (save as permitted under VCT rules) to dividends or return of capital and no rights to redemption.

 

Performance

 

The performance of UK equity markets was strong during the final quarter of 2017.

 

The FTSE All Share Index recorded a total return of +5.0% during the period under review, while the FTSE AIM All Share Index ended the quarter up by +4.9%, on the same total return basis.

 

UK equity indices continued to rise, despite ongoing uncertainty surrounding BREXIT and a relatively weak domestic economy. Much of the gains in the main and alternative markets have come from larger companies that operate on a global scale as they continue to benefit from the ongoing weakness of Sterling relative to the world's other major currencies.

 

The Company's overall performance was modestly positive during the period under review, with Net Asset Value per share increasing by 0.8%. Having started the period at 163.1 pence per share, the unaudited NAV per share as at 31 December 2017 was 164.4 pence per share.

 

VCT Qualifying Investments

Of the 75 VCT qualifying investments held in the portfolio, 34 recorded share price gains during the period under review. Of these, 14 investments generated capital gains in excess of £150,000 each.

Of particular note were the five largest contributors to performance, which generated a combined total of over £6.3 million in realised and unrealised capital gains in the period under review.

In absolute terms, the five stocks that delivered the greatest contribution were:-

AB Dynamics (+73.7%), a company engaged in the design, manufacture and supply of advanced testing and measurement products to the global automotive industry.

Fusion Antibodies (+159.8%), a contract research organisation providing a range of antibody engineering services.

Tracsis (+17.1%), a group that specialises in solving a variety of data capture, and resource optimisation problems, predominantly for the transport sector.

ULS Technology (+16.8%), a provider of online technology solutions for the UK conveyancing market.

Wey Education (+94.9%), a provider of online educational services worldwide.

 

Thirteen VCT qualifying holdings delivered negative contributions of more than £150,000 each.

 

Of these, three investee companies experienced share price falls that were directly related to unexpectedly poor trading or specific operational issues, while the remainder experienced share price weakness linked to market uncertainty and weak investor sentiment.

 

In absolute terms the five largest detractors from performance were:-

 

Animalcare (-12.9%), a veterinary medicines and animal products business.

 

Cohort (-16.5%), a holding company for a group of businesses supplying advanced technology products and services to the defence, security and transport markets  

 

IDOX (-43.6%), a leading supplier of specialist information management solutions and services.

 

Mattioli Woods (-8.4%), one of the UK's leading providers of Wealth Management and Employee Benefit Services.

 

Totally (-40.3%), a provider of healthcare services designed to offer improved care for those whose conditions can be better treated at home, locally, or in the community.

 

Non-Qualifying Investments

The overall performance of the non-qualifying investments was stable during the period under review, with an absence of notable newsflow on which to report.

 

Material Transactions

 

Three new VCT qualifying investments have been made during the period. In total, £4.8 million of new capital was allocated to these investments.

 

Additional VCT qualifying shares, to the value of £0.6 million, were acquired in Hardide, as part of a placing of new shares.

 

The only outright sale in the period was Greene King, which was a non-qualifying investment.

A number of partial disposals were made during the period. The purpose of such disposals is threefold; to help manage liquidity requirements, to ensure stock specific risk is contained and to lock in capital profits for future distribution to Shareholders via dividend payments.

Top Ten VCT Qualifying Holdings at 31 December 2017

Stock

% of fund

Abcam

7.9

Tracsis

4.2

Anpario

4.0

Mattioli Woods

3.7

MaxCyte

3.3

ULS Technology

2.8

Animalcare Group

2.6

Tristel

2.1

Cohort

2.0

Keywords Studios

2.0

Total

34.6%

 

Share Buy-Backs

 

During the period from 1 October 2017 to 31 December 2017, the Company bought back 509,200 of its own Ordinary Shares for cancellation, at an average price of 140.14 pence per share.

 

There were 118,889,237 Ordinary Shares in issue as at 31 December 2017.

 

Dividends

The Board has recommended a final dividend of 3.5 pence per share for the financial year ended 30 September 2017. The proposed dividend was approved by Shareholders at the Company's Annual General Meeting, which was held on 11 January 2018, and will be paid on 2 February 2018 to Shareholders on the register on 12 January 2018.

An interim dividend of 3.0 pence per share was paid on 11 August 2017. Total dividends paid in respect of the financial year ended 30 September 2017, will therefore amount to 6.5 pence per share (2016: 6.25 pence per share).

Material Events

 

On 17 November 2017, the Board announced the closure of the Offer for Subscription launched on 25 July 2017, which raised £33.6 million net of costs.

 

There were no other material events during the period from 1 October 2017 to 31 December 2017.

 

Chris Hutchinson

Unicorn Asset Management

Investment Manager

 

16 January 2018

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZMGMMMVRGRZM
Date   Source Headline
8th May 20249:47 amRNSNet Asset Value(s)
8th Apr 20241:46 pmRNSNet Asset Value(s)
2nd Apr 202410:46 amRNSTotal Voting Rights
18th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 202412:00 pmRNSDirector/PDMR Shareholding
11th Mar 202411:59 amRNSTotal Voting Rights
11th Mar 202411:57 amRNSIssue of Equity
7th Mar 202411:34 amRNSNet Asset Value(s)
1st Mar 202410:54 amRNSTotal Voting Rights
15th Feb 20244:30 pmRNSOffer for Subscription Update
14th Feb 20241:36 pmRNSDirector/PDMR Shareholding
14th Feb 202410:23 amRNSIssue of Equity
8th Feb 20243:47 pmRNSOffer for Subscription - Update
7th Feb 20245:43 pmRNSResult of AGM
5th Feb 20243:37 pmRNSNet Asset Value(s)
1st Feb 20242:53 pmRNSInterim Management Statement
26th Jan 202411:47 amRNSOffer for Subscription and Issue of Prospectus
11th Jan 20247:00 amRNSDividend Declaration
9th Jan 202410:39 amRNSNet Asset Value(s)
20th Dec 20233:06 pmRNSDirector Declaration
8th Dec 20237:00 amRNSFinal Results
6th Dec 20233:47 pmRNSNet Asset Value(s)
28th Nov 202310:00 amRNSIntention to launch an Offer
6th Nov 20234:48 pmRNSNet Asset Value(s)
17th Oct 20235:04 pmRNSNet Asset Value(s)
2nd Oct 20239:19 amRNSTotal Voting Rights
25th Sep 20239:18 amRNSTransaction in Own Shares
7th Sep 202311:40 amRNSNet Asset Value(s)
1st Sep 202311:39 amRNSTotal Voting Rights
25th Aug 20239:16 amRNSTransaction in Own Shares
14th Aug 202312:42 pmRNSDirector/PDMR Shareholding
11th Aug 20231:47 pmRNSIssue of Equity under Dividend Reinvestment Scheme
4th Aug 202310:57 amRNSNet Asset Value(s)
1st Aug 202310:19 amRNSTotal Voting Rights
19th Jul 20237:00 amRNSTransaction in Own Shares
7th Jul 20239:12 amRNSNet Asset Value(s)
3rd Jul 202312:23 pmRNSTotal Voting Rights
9th Jun 20234:11 pmRNSTransaction in Own Shares
6th Jun 20232:18 pmRNSHolding(s) in Company
5th Jun 20234:43 pmRNSNet Asset Value(s)
31st May 20237:00 amRNSHalf-year Report
5th May 20239:20 amRNSNet Asset Value(s)
6th Apr 202310:53 amRNSNet Asset Value(s)
3rd Apr 202310:25 amRNSTotal Voting Rights
10th Mar 20234:32 pmRNSTransaction in Own Shares
3rd Mar 20235:36 pmRNSNet Asset Value(s)
1st Mar 20239:52 amRNSTotal Voting Rights
22nd Feb 20234:04 pmRNSDirector/PDMR Shareholding
22nd Feb 20239:14 amRNSIssue of Equity
21st Feb 202311:43 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.